Pfizer: BRAFTOVI Combination Regimen Shows Significant Improvement In PFS In Phase 3 Trial In MCRC
Drug major Pfizer Inc. (PFE) announced Monday positive topline results from the progression-free survival or PFS analysis of the ...
Pfizer's BRAFTOVI shows promise in colorectal cancer trial
NEW YORK - Pfizer Inc. (NYSE: NYSE:PFE), a pharmaceutical giant with a market capitalization of $150 billion and annual revenue exceeding $59 billion, announced today that its Phase 3 BREAKWATER study ...
Is Pfizer Inc. (PFE) the Best Cancer Stock to Buy According to Hedge Funds?
We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...
Le Lézard2h
Pfizer's BRAFTOVI® Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 BREAKWATER Trial
Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...
Pfizer’s Braftovi improves survival in Phase 3 colorectal cancer trial
Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...
Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could ...
FDA approves new pain medication as an alternative to opioids: What to know about Journavx
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
STAT3d
With little fanfare, Biden administration stacked vaccine advisory committee with new members
With little fanfare, the Biden administration stacked a critical committee that helps set U.S. vaccination policy with new ...
FDA approves new painkiller that shows promise and challenges of opioid alternatives
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
KTVZ3d
FDA approves first new type of pain medication in 25 years
The US Food and Drug Administration signed off Thursday on the first new type of pain reliever to be approved in more than two decades. The drug, suzetrigine, is a 50-milligram prescription pill ...
MM&M3d
Rx Rundown: Merck, Biogen, Pfizer and more
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...